Overall, the study results indicated that macrophages with elevated TBC1D1 levels may play a crucial role in immunotherapy resistance and can act as a compelling biomarker when predicting the chances of survival for patients with gliomas. This evidence concerns the gene TBC1D1 and central nervous system cancer.